Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$35.12 USD
+0.15 (0.43%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $35.12 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Tandem Diabetes Care, Inc. (TNDM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$32.45 | $40.00 | $18.00 | -7.21% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Tandem Diabetes Care, Inc. comes to $32.45. The forecasts range from a low of $18.00 to a high of $40.00. The average price target represents a decline of 7.21% from the last closing price of $34.97.
Analyst Price Targets (11)
Broker Rating
Tandem Diabetes Care, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.93 a month ago based on 14 recommendations.
Of the 13 recommendations deriving the current ABR, seven are Strong Buy, representing 53.85% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 8 | 7 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 6 | 6 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 1.93 | 2.07 | 2.15 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/22/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
2/21/2024 | Raymond James | Jayson T Bedford | Hold | Hold |
2/20/2024 | Lake Street Capital Markets | Brooks G O'Neil | Not Available | Strong Buy |
10/16/2023 | SVB Securities | Michael Kratky | Not Available | Hold |
8/4/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 13 |
Average Target Price | $32.45 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 95 of 252 |
Current Quarter EPS Est: | -0.80 |